<?xml version="1.0" encoding="UTF-8"?>
<p id="Par69">In patients treated with intravenous methylprednisolone for multiple sclerosis flareups, there are diverse acute symptomatic side effects, including abdominal pain, nausea, and vomiting, disturbed sleep, and neurobehavioral changes such as confusion, irritability, and restlessness [
 <xref ref-type="bibr" rid="CR92">92</xref>]. Common clinical laboratory findings are hyperglycemia, hypokalemia, increased blood pressure, and anti-inflammation. All these aspects may be relevant to neurobehavioral and clinical laboratory abnormalities in COVID-19 because of the frequent use of high-dose steroids as part of management in the intensive care setting.
</p>
